Bioventus
BVS
Bioventus (BVS) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 27, 2026
- EPS actual
- $0.22
- EPS estimate
- $0.21
- EPS surprise
- +2.95%
- Revenue surprise
- −1.10%
- Revenue
- $153.2M
- Revenue estimate
- $154.9M
- Reported
- Aug 5, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $0.21 | $0.22 | +2.95% | $153.2M | SEC |
| Q1 2026 | May 6, 2026 | $0.07 | $0.15 | +117.71% | $132.1M | SEC |
| Q4 2025 | Mar 5, 2026 | $0.22 | $0.24 | +11.21% | $157.9M | SEC |
| Q3 2025 | Nov 4, 2025 | $0.10 | $0.15 | +43.27% | $138.7M | SEC |
| Q2 2025 | Aug 6, 2025 | $0.16 | $0.21 | +33.67% | $147.7M | SEC |
| Q1 2025 | May 6, 2025 | $0.02 | $0.08 | +225.20% | $123.9M | SEC |
| Q4 2024 | Mar 11, 2025 | $0.08 | $0.15 | +81.60% | $153.6M | SEC |
| Q3 2024 | Nov 5, 2024 | $0.02 | $0.06 | +270.37% | $139.0M | SEC |
| Q2 2024 | Aug 6, 2024 | $0.07 | $0.19 | +182.74% | $151.2M | SEC |
| Q1 2024 | May 7, 2024 | −$0.07 | $0.07 | +204.95% | $129.5M | SEC |
| Q4 2023 | Mar 12, 2024 | $0.02 | $0.07 | +266.49% | $135.4M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.02 | $0.05 | +350.00% | $120.8M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.00 | $0.14 | +4342.42% | $137.1M | SEC |
| Q1 2023 | May 16, 2023 | −$0.15 | −$0.26 | −73.33% | $119.1M | SEC |
| Q4 2022 | Mar 31, 2023 | $0.05 | −$0.06 | −225.00% | $125.8M | SEC |
| Q3 2022 | Nov 8, 2022 | $0.12 | $0.08 | −34.91% | $137.1M | SEC |
| Q2 2022 | Aug 11, 2022 | $0.16 | $0.10 | −35.82% | $140.3M | SEC |
| Q1 2022 | May 10, 2022 | $0.05 | $0.04 | −16.14% | $117.3M | SEC |
| Q4 2021 | Mar 10, 2022 | $0.18 | $0.26 | +47.48% | $130.4M | SEC |
| Q3 2021 | Nov 9, 2021 | $0.14 | $0.25 | +77.94% | $108.9M | SEC |
Quarterly revenue
Frequently asked questions
When did Bioventus (BVS) last report earnings?
Bioventus last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did BVS beat earnings estimates?
Yes. Bioventus reported EPS of $0.22 for Q2 2026 against a $0.21 estimate — a 2.95% beat.
How much revenue did BVS report last quarter?
Bioventus reported $153.2M in revenue for Q2 2026, against a consensus estimate of $154.9M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.